NASDAQ · ABVX
Healthcare · Biotechnology
$114.95
Down-$3.25 (-2.75%)
Updated Aug 22, 2026, 2:30 AM
SID Score
4.5/10
Composite research score
Smart Money
57/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ABVX closed at $118.20 after 20 trading sessions, down 5.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $120.00 | $120.11 | $116.20 | $118.195 | 1.19M |
| Aug 19, 2026 | $120.33 | $121.08 | $119.08 | $120.56 | 637.08K |
| Aug 18, 2026 | $120.00 | $121.25 | $118.50 | $118.94 | 482.01K |
| Aug 17, 2026 | $118.88 | $123.4199 | $118.7163 | $120.73 | 894.8K |
| Aug 14, 2026 | $120.74 | $121.97 | $117.90 | $118.96 | 903.83K |
| Aug 13, 2026 | $126.28 | $126.28 | $120.55 | $121.45 | 812.8K |
| Aug 12, 2026 | $126.81 | $128.19 | $125.22 | $125.52 | 525.37K |
| Aug 11, 2026 | $127.85 | $128.50 | $125.08 | $126.81 | 466.24K |
| Aug 10, 2026 | $129.92 | $130.50 | $127.12 | $127.50 | 763.96K |
| Aug 7, 2026 | $132.05 | $133.52 | $130.01 | $130.93 | 1.1M |
| Aug 6, 2026 | $126.00 | $131.25 | $125.64 | $130.00 | 1.08M |
| Aug 5, 2026 | $126.39 | $130.07 | $125.17 | $125.39 | 660.07K |
| Aug 4, 2026 | $125.01 | $126.00 | $123.84 | $125.19 | 634.91K |
| Aug 3, 2026 | $120.40 | $126.00 | $119.53 | $124.78 | 941.54K |
| Jul 31, 2026 | $127.26 | $127.51 | $120.62 | $124.92 | 1.24M |
| Jul 30, 2026 | $119.60 | $125.39 | $119.00 | $124.33 | 1.49M |
| Jul 29, 2026 | $124.90 | $125.24 | $118.1801 | $118.84 | 1.15M |
| Jul 28, 2026 | $126.21 | $126.50 | $121.70 | $124.23 | 1.02M |
| Jul 27, 2026 | $125.93 | $130.00 | $124.0001 | $128.00 | 662.35K |
| Jul 24, 2026 | $133.15 | $133.23 | $125.68 | $125.70 | 950.97K |
The latest Smart Investors Daily articles mentioning ABVX.
ABVX research
Company profile and research snapshot.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 5, 2026 | ODDO BHF | Buy | — |
| Jul 1, 2026 | STIFEL EUROPE | Buy | — |
| Jun 29, 2026 | BTIG | Buy | — |
| Jun 29, 2026 | LIFESCI CAPITAL | Outperform | — |
| Feb 23, 2026 | STIFEL EUROPE | Buy | — |
No generated briefing is available yet.
ChartMill · Aug 11, 2026
ABVX shows a strong breakout setup with 9/10 technical and setup ratings, consolidating near resistance. High relative strength and clear entry/stop levels make it one to watch.
Yahoo · Aug 4, 2026
PARIS, August 04, 2026--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mu
Yahoo · Jul 30, 2026
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026 PARIS, France – July 30, 2026 – 10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulato
Benzinga · Jul 30, 2026
Abivax SA (Euronext PARIS:FR0012333284 – ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABVX.
